Guérois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos A M, Négrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M
Hemophilia Center of Tours, France.
Thromb Haemost. 1995 Feb;73(2):215-8.
The incidence of factor VIII inhibitor was studied in a cohort of 56 previously untreated patients with severe hemophilia A (factor VIII below 1 U/dl). They received only one brand of highly purified factor VIII concentrate (HPSD-VIII) prepared by conventional chromatography with a solvent-detergent step for viral inactivation. Follow-up since the first infusion of HPSD-VIII was from 1 to 76 months (mean = 29) and cumulative exposure days (CED) from 1 to over 100 (median = 26). Five patients (9%) developed an inhibitor after 6 to 19 CED, only one being a high responder (2%), showing a low incidence of inhibitor compared with previous studies using high purity plasma-derived or recombinant products.
